



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO. 03/402,092	FILING DATE 03/23/01	FIRST NAMED INVENTOR CHSUYE	ATTORNEY DOCKET NO. 001560-373
-------------------------------	-------------------------	--------------------------------	-----------------------------------

021839 HM12/0323
BURNS DOANE SWECKER & MATHIS L L P
POST OFFICE BOX 1404
ALEXANDRIA VA 22313-1404

EXAMINER SLOBODYANSKY, E

ART UNIT 1652	PAPER NUMBER 6
------------------	-------------------

DATE MAILED: 03/23/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
1652	6

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner **Elizabeth Slobodyansky**, Art Unit **1652**, whose telephone number is **(703) 306- 3222**.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Elizabeth Slobodyansky, PhD
Primary Examiner
Art Unit 1652

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Raw Sequence Listing Error Summary

5

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09/402,093

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 Wrapped Aminos The amino acid number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4 Misaligned Amino Acid The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
Numbering between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5 Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6 Variable Length Sequence(s) contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and
indicate in the (ix) feature section that some may be missing.
- 7 PatentIn ver. 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid
sequence(s) . Normally, PatentIn would automatically generate this section from the
previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section
to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223>
sections for Artificial or Unknown sequences.
- 8 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
(OLD RULES) (2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
(NEW RULES) <210> sequence id number
 <400> sequence id number
 000
- 10 Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.
(NEW RULES) Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 Use of <213>Organism Sequence(s) are missing this mandatory field or its response.
(NEW RULES)
- 12 Use of <220>Feature Sequence(s) are missing the <220>Feature and associated headings.
(NEW RULES) Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 13 PatentIn ver. 2.0 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.

BEST AVAILABLE COPY

RAW SEQUENCE LISTING DATE: 03/22/2001
 PATENT APPLICATION: US/09/402,093 TIME: 09:36:28

Input Set : A:\F962 SEQUENCE.txt
 Output Set: N:\CRF3\03222001\I402093.raw

Does Not Comply
 Corrected Diskette Needed

3 <110> APPLICANT: Suntory Limited
 5 <120> TITLE OF INVENTION: Process for producing peptides using a
 6 helper peptide
 8 <130> FILE REFERENCE: F962
 10 <140> CURRENT APPLICATION NUMBER: US/09/402,093
 10 <141> CURRENT FILING DATE: 1999-09-29
 10 <150> PRIOR APPLICATION NUMBER: JP 10-032272
 11 <151> PRIOR FILING DATE: 1998-01-30
 13 <160> NUMBER OF SEQ ID NOS: 24

ERRORED SEQUENCES

424 <210> SEQ ID NO: 24
 425 <211> LENGTH: 5
 426 <212> TYPE: PRT
 427 <213> ORGANISM: Artificial Sequence
 429 <220> FEATURE:
 430 <223> OTHER INFORMATION: Amino acid sequence containing a site cleaved by
 431 Kex2 Protease
 433 <400> SEQUENCE: 24
 434 Ser Cys His Lys Arg
 435 1 5
 E--> 436 ??
 E--> 444 - 10/13 -
 E--> 446 - 1/13 -

delete at end of file

see next page for more errors

BEST AVAILABLE COPY

2

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/402,093

DATE: 03/22/2001
TIME: 10:04:17

Input Set : A:\PTO.AMC.txt
Output Set: N:\CRF3\03222001\I402093.raw

3 <110> APPLICANT: Suntory Limited
5 <120> TITLE OF INVENTION: Process for producing peptides using a
6 helper peptide
8 <130> FILE REFERENCE: F962
C--> 10 <140> CURRENT APPLICATION NUMBER: US/09/402,093
C--> 10 <141> CURRENT FILING DATE: 1999-09-29
10 <150> PRIOR APPLICATION NUMBER: JP 10-032272
11 <151> PRIOR FILING DATE: 1998-01-30
13 <160> NUMBER OF SEQ ID NOS: 24
15 <210> SEQ ID NO: 1
16 <211> LENGTH: 4
17 <212> TYPE: PRT
18 <213> ORGANISM: Artificial Sequence
20 <220> FEATURE:
21 <223> OTHER INFORMATION: Amino acid sequence adjacent to a site cleaved by
22 enterokinase
24 <400> SEQUENCE: 1
25 Asp Asp Asp Lys
26 1
28 <210> SEQ ID NO: 2
29 <211> LENGTH: 4
30 <212> TYPE: PRT
31 <213> ORGANISM: Artificial Sequence
W--> 32 <220> FEATURE:
33 <223> OTHER INFORMATION: Amino acid sequence adjacent to a site cleaved by
34 blood coagulation Factor Xa
W--> 35 <400> SEQUENCE: 2
36 Ile Glu Gly Arg
37 1
40 <210> SEQ ID NO: 3
41 <211> LENGTH: 7
42 <212> TYPE: PRT
43 <213> ORGANISM: Artificial Sequence
45 <220> FEATURE:
46 <223> OTHER INFORMATION: Amino acid sequence containing a site cleaved by
47 renin
49 <400> SEQUENCE: 3
50 Pro Phe His Leu Leu Val Tyr
51 1 5
53 <210> SEQ ID NO: 4
54 <211> LENGTH: 6
55 <212> TYPE: PRT
56 <213> ORGANISM: Artificial Sequence
58 <220> FEATURE:
59 <223> OTHER INFORMATION:
61 <400> SEQUENCE: 4
62 Val Asp Asp Asp Asp Lys

→ see item 12 on Enr Summary Sheet

BEST AVAILABLE COPY

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/402,093

DATE: 03/22/2001
TIME: 09:36:29

Input Set : A:\F962 SEQUENCE.txt
Output Set: N:\CRF3\03222001\I402093.raw

L:10 M:270 C: Current Application Number differs. Replaced Current Application No
L:10 M:271 C: Current Filing Date differs. Replaced Current Filing Date
L:29 M:283 W: Missing Blank Line separator, <220> field identifier
L:29 M:256 W: Invalid Numeric Header Field, <220> has non-blank data
L:31 M:282 W: Numeric Field Identifier Missing, <211> is required.
L:31 M:282 W: Numeric Field Identifier Missing, <212> is required.
L:31 M:282 W: Numeric Field Identifier Missing, <213> is required.
L:31 M:283 W: Missing Blank Line separator, <400> field identifier
L:436 M:333 E: Wrong sequence grouping. Amino acids not in groups:
L:436 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:1
L:444 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:24
L:444 M:333 E: Wrong sequence grouping. Amino acids not in groups:
M:332 Repeated in SeqNo=24
L:446 M:333 E: Wrong sequence grouping. Amino acids not in groups:

BEST AVAILABLE COPY